Table 2.
Children with overt hypothyroidism (OH) characteristics.
| OH at baseline | SH patients (F) who developed OH | ||||
|---|---|---|---|---|---|
| Girl I | Girl II | Girl III | Girl IV | Girl V | |
| Age at baseline (years) | 15.2 | 10.2 | 14.3 | 0.8 | 0.8 |
| Age at end of FU (years) | 17.9 | 16.3 | 14.8 | 5.2 | 5.2 |
| Length of FU (months) | 32.8 | 73.5 | 5.2 | 52.0 | 52.1 |
| TSH (mIU/m)] at baseline | 77.8 | 5.9 | 10.5 | 10.0 | 10.0 |
| TSH (mIU/ml) at end of FU | 13.1 | 1.9 | 5.34 | 4.1 | 5.0 |
| fT4 (ng/dl) at baseline | 0.7 | 0.79 | 0.84 | 1.45 | 1.54 |
| fT4 (ng/dl) at end of FU | 1.0 | 1.7 | 0.78 | 0.78 | 0.76 |
| Presence of Abs | 1 | 1 | 0 | 1 | 1 |
| CHD | 1 | 0 | 0 | 1 | 0 |
| hSDS at baseline | −1.4 | 1.9 | 2.4 | 0.3 | 0.0 |
| hSDS at end of FU | −1.3 | 1.5 | 2.7 | 0.9 | 0.9 |
| BMI (kg/m2) | 18.9 | 24.8 | 27.7 | 15.5 | 14.3 |
| Dosage of L-T4 (µg/kg/day) | 1.6 | 1.1 | 0.5 | 2.7 | 2.5 |
| Other autoimmune diseases | – | – | AA, AD | DMt1 | – |
| Diagnosis at end of FU | OH | OH | OH | OH | OH |
SH, subclinical hypothyroidism; OH, overt hypothyroidism; EuT, euthyroid patients; SH-T1, patients from group SH with levothyroxine treatment; SH-T0, patients from group SH without treatment; F, female; M, male; FU, follow-up; SD, standard deviation; TSH, thyroid-stimulating hormone; fT4, free thyroxine; Abs, antithyroid autoantibodies; CHD, congenital heart disease; hSDS, height standard deviation score; BMI, body mass index; L-T4, levothyroxine; AA, alopecia aerata; AD, atopic dermatitis; DMt1, diabetes type 1; CD, coeliac disease.